Marleen Wingen1, Kim P C Kuypers, Johannes G Ramaekers. 1. Faculty of Psychology, Department of Neurocognition (Experimental Psychopharmacology Unit), Brain and Behaviour Institute, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands. m.wingen@psychology.unimaas.nl
Abstract
RATIONALE: Various studies have demonstrated a modulating role for serotonin in attention. Selective serotonin inhibitors have repeatedly been shown to impair performance in sustained attention tasks. OBJECTIVES: To assess the contribution of serotonin reuptake inhibition and specific blockade of the pre-synaptic 5-HT(1a) receptor and the 5-HT(2a) receptor to deficits in attention. MATERIALS AND METHODS: The study was conducted according to a randomized, double-blind, placebo controlled, four-way crossover design including 16 healthy volunteers. Treatments consisted of oral administration of the selective serotonin reuptake inhibitor (SSRI) escitalopram 20 mg + placebo; escitalopram 20 mg + ketanserin (5-HT(2a) antagonist), 50 mg; escitalopram20 mg + pindolol (5-HT(1a) antagonist) 10 mg; and placebo + placebo on four separate days. A range of performance tasks were conducted to assess the subjects' attention and motor functions. RESULTS:Escitalopram administered alone impaired tracking performance in a divided attention task. The combination of escitalopram and pindolol and escitalopram and ketanserin impaired divided attention as compared to placebo. In addition, escitalopram and ketanserin impaired sustained attention. Divided attention impairment observed after combined treatments did not significantly differ from impairments after escitalopram alone. Sustained attention impairment observed after combined escitalopram and ketanserin significantly differed from escitalopram alone. CONCLUSIONS:5HT(1a) blockade hardly affected SSRI effects on attention. Additional 5HT(2a) blockade, however, produced impairments of sustained attention and motor impulse control.
RCT Entities:
RATIONALE: Various studies have demonstrated a modulating role for serotonin in attention. Selective serotonin inhibitors have repeatedly been shown to impair performance in sustained attention tasks. OBJECTIVES: To assess the contribution of serotonin reuptake inhibition and specific blockade of the pre-synaptic 5-HT(1a) receptor and the 5-HT(2a) receptor to deficits in attention. MATERIALS AND METHODS: The study was conducted according to a randomized, double-blind, placebo controlled, four-way crossover design including 16 healthy volunteers. Treatments consisted of oral administration of the selective serotonin reuptake inhibitor (SSRI) escitalopram 20 mg + placebo; escitalopram 20 mg + ketanserin (5-HT(2a) antagonist), 50 mg; escitalopram 20 mg + pindolol (5-HT(1a) antagonist) 10 mg; and placebo + placebo on four separate days. A range of performance tasks were conducted to assess the subjects' attention and motor functions. RESULTS:Escitalopram administered alone impaired tracking performance in a divided attention task. The combination of escitalopram and pindolol and escitalopram and ketanserin impaired divided attention as compared to placebo. In addition, escitalopram and ketanserin impaired sustained attention. Divided attention impairment observed after combined treatments did not significantly differ from impairments after escitalopram alone. Sustained attention impairment observed after combined escitalopram and ketanserin significantly differed from escitalopram alone. CONCLUSIONS: 5HT(1a) blockade hardly affected SSRI effects on attention. Additional 5HT(2a) blockade, however, produced impairments of sustained attention and motor impulse control.
Authors: E A Rabiner; Z Bhagwagar; R N Gunn; P A Sargent; C J Bench; P J Cowen; P M Grasby Journal: Am J Psychiatry Date: 2001-12 Impact factor: 18.112
Authors: E A Rabiner; R N Gunn; M R Wilkins; P A Sargent; E Mocaer; E Sedman; P J Cowen; P M Grasby Journal: Nucl Med Biol Date: 2000-07 Impact factor: 2.408
Authors: Eugenii A Rabiner; Zubin Bhagwagar; Roger N Gunn; Philip J Cowen; Paul M Grasby Journal: Neuropsychopharmacology Date: 2004-09 Impact factor: 7.853
Authors: Karine Madsen; David Erritzoe; Erik Lykke Mortensen; Anders Gade; Jacob Madsen; William Baaré; Gitte M Knudsen; Steen G Hasselbalch Journal: Psychopharmacology (Berl) Date: 2010-07-10 Impact factor: 4.530